Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Pittsburgh
With
National Institute on Drug Abuse (NIDA)
This study pilot tests a 13-week distress tolerance-based psychosocial intervention paired with a benzodiazepine taper comparing it to a relaxation therapy control condition with the aim of assisting individuals receiving OAT discontinue benzodiazepine use. All participants will receive the same benzodiazepine (BZD) discontinuation protocol. The Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention consists of 13 weeks with 5 weekly therapy sessions prior to a 9-week BZD taper. Some participants may be prescribed non-benzodiazepine medications to treat the underlying conditions for which they were using BZDs \[e.g. selective serotonin reuptake inhibitors (SSRI) for anxiety or hypnotics for insomnia\]. Data collection will occur at baseline, then weekly for 13 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 or older
Receiving OAT (methadone or buprenorphine) for at least 2 weeks
Regular BZD use defined by BZD use 3 or more times per week in past month by self-report and positive urine screen at time of recruitment
Provides permission to contact current BZD prescriber if being prescribed BZDs
Speaks English
Wants to discontinue BZD use
Capacity to provide informed consent
You may not be if
Pregnant, confirmed by urine pregnancy test
Cognitive impairment, as indicated by Montreal Cognitive Assessment (MoCA): must score at least 26 on the MoCA with a one-point adjustment for individuals with formal education of 12 years or fewer
Any past month illicit opioid determined by self-report or urine drug test; illicit defined as non-medical use
Receiving ongoing psychosocial treatment for BZD use disorder
Uncontrolled seizure disorder (i.e. seizure in prior 90 days), or past BZD withdrawal seizure
Current suicidality or homicidality
Current psychotic symptoms
Clareo Health | Distress Tolerance for Benzodiazepine Discontinuation